OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing novel therapies targeting cancer stem cells. The company has five anticancer candidates in clinical development, including demcizumab (Anti-DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc). These candidates target key signaling pathways in cancer stem cells, including the Notch and Wnt signaling pathways.OncoMed also has two additional antibodies in preclinical development: an Anti-DLL4/Anti-VEGF bispecific antibody and Anti-RSPO3. The company plans to submit relevant Investigational New Drug (IND) applications in early 2014. Additionally, OncoMed continues to focus on discovering additional novel anti-CSC candidates.